qypytcuvy.blogspot.com
Meelia had been a Haemonetics director since 2005 and his term was set to expiresin 2011. The company said Meelia stepped down to spend more time and energt in his executive role atCovidien (NYSE: COV), a Bermuda-based developer of medical devices and imaginv solutions, among other health care according to a filing with the . In a separate regulatoryu filing Wednesday, the company outlined the compensation parameters for newl hired CEO Brian Concannon and executive chairman Brad Concannon willreceive $550,000 in salarh and stands to earn another $412,500 in bonuses if certaim operating and management milestones are met.
Concannon also receiveed options tobuy 32,854 shares of Haemonetics common stock and was granteds 2,053 shares of its restricted Haemonetics (NYSE: HAE), based in Braintree, also outlined several change-in-controlp provisions that could pay Concannon up to threew times his annual pay if a company or person acquirezs 35 percent of Haemonetics common stock. Nutter, the company’s former CEO, will receive $300,000 in annual pay as both Haemonetics board’s executive chairman. He also remains an employee ofthe company, although his role was not detailee in Wednesday’s filing.
No comments:
Post a Comment